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Abstract
Dendritic cells (DCs) play a central role in initiating immune responses. Some persistent viruses infect DCs and can disrupt
their functions in vitro. However, these viruses remain strongly immunogenic in vivo. Thus what role DC infection plays in
the pathogenesis of persistent infections is unclear. Here we show that a persistent, B cell-tropic gamma-herpesvirus, Murid
Herpesvirus-4 (MuHV-4), infects DCs early after host entry, before it establishes a substantial infection of B cells. DC-specific
virus marking by cre-lox recombination revealed that a significant fraction of the virus latent in B cells had passed through a
DC, and a virus attenuated for replication in DCs was impaired in B cell colonization. In vitro MuHV-4 dramatically altered the
DC cytoskeleton, suggesting that it manipulates DC migration and shape in order to spread. MuHV-4 therefore uses DCs to
colonize B cells.
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Introduction
Dendritic cells (DCs) act as sentinels against infection: they
encode pathogen-responsive receptors, abound at pathogen entry
sites, and orchestrate both innate and adaptiveimmune responses
[1,2]. Virus-infected DCs are generally immunogenic [3–5], and
DC infection may be important for optimal T cell priming [6].
However several persistent viruses, which might be expected to
limit their exposure to host immunity, efficiently infect DCs [7–
10]. The infected DCs may function abnormally in vitro [11,12],
but the corresponding in vivo infections remain potently immuno-
genic. Therefore how DC infection benefits these persistent
viruses, or whether it instead benefits the host, is unclear.
Murid Herpesvirus-4 (MuHV-4) is a gamma-herpesvirus that
readily allows in vivo analysis of host colonization [13,14]. Like
Epstein-Barr virus and the Kaposi’s Sarcoma-associated Herpes-
virus, MuHV-4 persists in B cells [15,16]. It also acutely infects
macrophages and dendritic cells [17–19]. Myeloid infection
provides MuHV-4 with a site of persistence in B cell-deficient
mice, but the antibody deficiency of these mice leads to a
somewhat atypical chronic lytic infection [20]; in immunocompe-
tent mice, infected macrophages and dendritic cells are hard to
detect long-term [19]. Therefore myeloid infection seems more
likely to be important for establishing MuHV-4 host colonization
than for maintaining it. Epstein-Barr virus and Kaposi’s Sarcoma-
associated Herpesvirus can also infect myeloid cells in vitro [9,21].
While they seem rarely to do so in vivo, their clinical presentations
post-date infection by at least 1 month [22], so early host
colonization is rarely studied. Thus acute myeloid cell infection
may not be unique to MuHV-4.
The difficulty of curing established gamma-herpesvirus infec-
tions makes early events in host colonization important to
understand. It has been suggested that incoming Epstein-Barr
virus infects B cells and so establishes latency directly [23]. This
would argue against an important role for myeloid infection.
However, good supporting evidence for direct B cell infection is
lacking. Indeed vaccination to block Epstein-Barr virions binding
to B cells failed to reduce the incidence of infection [24]. And
while DNA from lung-inoculated, replication-deficient MuHV-4
has been found associated with B cells [25,26], viral genome-
positive B cells did not reach the spleen, so whether the detected
DNA was a viable primary infection or merely adsorbed debris
was unclear. That fibroblast-propagated MuHV-4 infects mice
well [27] and B cells poorly [28] would argue against B cells being
a significant primary target. Natural host entry probably occurs via
the upper respiratory tract rather than the lung [29], but MuHV-4
lacking thymidine kinase or ribonucleotide reductase fails to infect
by this route and neither enzyme is required for replication in B
cells [30,31]. Therefore here too B cells would seem an unlikely
primary target.
How then does MuHV-4 reach B cells? HIV can infect T cells
via DCs [32,33], and DCs also communicate with B cells [34], so
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exploiting DC/lymphocyte interactions could be a common theme
among lymphotropic viruses. However, in vivo evidence is again
sparse. HIV-infected DCs are hard to find in vivo, and most HIV
taken up by DCs in vitro is degraded. Thus it has been possible only
to hypothesize that DCs contribute to host entry [35]. MuHV-4
allows more comprehensive analysis, and this is what we
undertook here. As removing DCs causes immunosuppression
[36], we used DC-specific cre recombinase expression to inhibit
MuHV-4 replication in DCs or to mark genetically viruses that
had replicated in a DC, while leaving normal DC functions intact.
Results
Direct visualization of MuHV-4 spread
That MuHV-4 colonizes B cells is indisputable, but where it first
infects them is unclear. To identify the likely anatomical site we
used viral luciferase expression [29] to track host colonization after
upper respiratory tract infection (Fig. 1). Live imaging signals were
evident in noses 3 days after inoculation and in the neck after 10
days (Fig.1a). Signals were present in both sites after 6 days,
indicating that the virus spread from nose to neck at 3–6 days post-
infection.
Ex vivo imaging of dissected tissues at the peak of neck infection -
day 10 - (Fig.1b) established that this signal came entirely from the
superficial cervical lymph nodes (SCLN), which receive lymphatic
drainage from the nose [37]. No other tissues were luciferase+ at
this time. Imaging dissected mice at day 6 (Fig. 1c) revealed
luciferase expression in the nasal turbinates and in the SCLN, but
not in intervening sites. Nor was luciferase expression evident in
other lymph nodes, or in the nasal-associated lymphoid tissue that
lies on either side of the palate. Therefore MuHV-4 appeared to
move directly from the nose to the SCLN.
Host colonization measured by viral DNA loads and
recoverable infectivity
We next tracked infection by quantitative PCR (Q-PCR) of viral
DNA (Fig. 2a). In agreement with the luciferase imaging, viral
genomes were detected in the nose at day 3 post-inoculation and
not consistently in the SCLN until day 5. Recovering replication-
competent virus by infectious centre assay (Fig. 2b) was less
sensitive but showed similar trends, arguing that the DNA signals
in the SCLN were due to infection rather than just accumulated
viral debris. Both upper and lower respiratory tract infections
showed viral genomes being most abundant in the peripheral
epithelial site at day 5 post-inoculation, and most abundant in
lymphoid tissue at day 14 (Fig. 2c). At day 5 viral genomes were
more abundant in draining lymph nodes than in spleens, whereas
by day 14 these sites were equivalent. These results were consistent
with epithelial infection seeding first to its draining lymph nodes,
and then disseminating to the spleen, presumably via B cells [38].
Kinetic comparison of DC and B cell infections
Previous analyses of MuHV-4 genome loads in different cell
types have focussed on peak splenic titers, when most infected cells
are B cells [18,19]. We reasoned that if B cells only became
infected once virus reached lymph nodes, then early on viral
genome loads might be lower in lymph node B cells than in the
cells first responsible for taking the virus there. Antigen transport
of lymph nodes is a major function of DCs. We therefore tested
whether DC infection might precede B cell infection, by separating
these sub-populations from acutely infected lymph nodes on
affinity columns and determining their viral genome loads by Q-
PCR (Fig. 2d). At days 11 and 14 after virus inoculation into either
noses or lungs, viral genome loads were higher in lymph node
B220+ cells (B cells) than in CD11c+ cells (DCs), but at days 5 and
8 they were higher in DCs.
Further analysis (Fig. 2e) identified significantly higher viral
genome loads also in CD11c-CD11b+ lymph node cells (macro-
phages) than in B cells early after virus inoculation into the lungs,
but not after virus inoculation into the nose. At 8 days after virus
inoculation into the upper respiratory tract, 105 cells purified from
the SCLN of pooled pairs of mice yielded 20.067.6 infectious
centres for macrophages, 53.3626.2 for DCs and 14.764.3 for B
cells (mean 6 SEM, n= 3). Each population yielded ,1 p.f.u. per
105 cells by plaque assay. Therefore after upper respiratory tract
infection, a predominantly latent infection of DCs appeared to
precede that of B cells. SCLN suspensions are typically 50% B cells
and ,5% DCs, so at all time points B cells accounted for most of
the recoverable viral DNA. However virus seeds to the SCLN at a
low level, is rapidly passed to B cells, which proliferate, and seeds
asynchronously between individual mice. Thus by the time DC
infection is readily detected, some B cell infection and amplifica-
tion has inevitably occurred. The kinetic changes in relative
genome load argued strongly for DC infection preceding B cell
infection: the genome+ DCs at day 14 may have acquired infection
from B cells, but this was unlikely at day 5 because B cell viral
loads then were low.
Identification of MuHV-4-infected DCs
We sought next to visualize infected cells directly, using MuHV-
4 that expresses eGFP from an intergenic EF1a promoter [39]
(Fig. 3). At day 11 post-infection - that is after the onset of virus-
driven lymphoproliferation - flow cytometry identified viral eGFP
expression mainly in B cells (Fig. 3a): approximately 1% of CD19+
lymph nodes cells were eGFP+. The eGFP+ cells were also positive
for surface immunoglobulin and MHC class II. Most were CD69+,
consistent with MuHV-4 up-regulating this acute activation
marker on B cells [40]. B cells are normally syndecan-4+ [41],
so a surprising finding was that most eGFP+ cells were syndecan-
4-. Syndecan-4 is a carrier of heparan sulfate, on which MuHV-4
infection strongly depends [42], so MuHV-4 may down-regulate
syndecan-4 on infected B cells to prevent super-infection.
No clear CD19-eGFP+ population was identifiable by flow
cytometry. However, immunohistochemistry at day 11 post-
Author Summary
We detect invading viruses with dendritic cells and
eliminate them with lymphocytes. A key interaction is
lymphocyte activation by dendritic cells presenting viral
antigens. Not all viruses can be eliminated, and some that
persist deliberately colonize lymphocytes and dendritic
cells, such that parasitism and host defence co-exist within
the same sites. Once established, these infections are very
hard to eliminate. Therefore to vaccinate against them we
must determine how infection first occurs. Here we show
that a gamma-herpesvirus relation of the Kaposi’s Sarco-
ma-associated Herpesvirus and Epstein-Barr virus - B cell-
tropic human pathogens that cause cancers - uses
dendritic cells to reach and infect B lymphocytes. Dendritic
cells were infected before B cells; viruses marked
genetically in dendritic cells were recovered from B cells;
and a virus unable to replicate in dendritic cells infected B
cells poorly. Thus dendritic cells not only present viral
antigens to lymphocytes, but can be exploited by evasive
viruses to infect lymphocytes. Therefore targeting dendrit-
ic cell infection could be an effective means of vaccine-
primed host defence.
MuHV-4 Exploits DCs
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infection identified both eGFP+B220+ and eGFP+CD11c+ cells in
lymph nodes (Fig. 3b). At day 7 (Fig. 3c) eGFP+ cells in the SCLN
were 64.0613.0% CD11c+, 14.165.1% B220+ and 21.9612.3%
neither (mean6 SEM, n= 6 mice, counting.100 eGFP+ cells per
mouse). At day 11, SCLN eGFP+ cells were 12.062.8% CD11c+,
78.062.4% B220+, and 10.063.1% neither. Therefore both PCR
of viral DNA and immunostaining of virus-expressed eGFP
showed DC infection early in lymph node colonization, before B
cell infection was well established. Our failure to detect a clear
population of infected DCs by flow cytometry possibly reflected
that these cells are difficult to isolate intact.
A marker virus for assaying exposure to cre recombinase
Cre-lox recombination allows transient infection events to be
recorded by a permanent genetic mark [43]. We used this
technology to identify MuHV-4 that had replicated in cre
recombinase+ cells, by inserting a loxP-flanked eCFP expression
cassette between the 39 ends of ORFs 57 and 58 (Fig. 4a). The
MuHV-4 BAC/eGFP cassette is also flanked by loxP sites [44], so
BAC-derived viruses retain a single loxP site at the genome left
end. To avoid recombination between this site and those flanking
eCFP, we incorporated a point mutation into the spacer region of
the latter. We then transfected BAC DNA into BHK-21 cells,
passed the recovered eGFP+eCFP+ virus once through cre+ NIH-
3T3 cells (2 p.f.u./cell) and selected eGFP-eCFP+ virus clones
from the mixed progeny (Fig. 4b).
LoxP-eCFP MuHV-4 (eGFP-eCFP+) showed no in vivo growth
deficit (Fig. S1). In vitro it rapidly lost eCFP expression when passed
through cre+ NIH-3T3 cells (Fig. 4c). We quantitated this loss by
counting plaques under phase contrast and typing each plaque as
eCFP+ or eCFP- under ultra-violet illumination (Fig. 4d). LoxP-
eCFP MuHV-4 also lost eCFP expression in cre+DCs - derived
Figure 1. Direct visualization of lymph node colonization after non-invasive MuHV-4 infection. a. Mice were infected with MuHV-4
expressing luciferase from a viral early lytic promoter (104 p.f.u. intranasally without anaesthesia). Infection was then tracked by injection with
luciferin and CCD camera scanning. Equivalent data were obtained with more than 20 mice. b. The live imaging signal at day 10 post-infection was
localized to the superficial cervical lymph nodes (SCLN, indicated by arrowheads). No signal was observed from the underlying salivary glands. c.
Dissection at day 6 post-infection revealed luciferase signals in the nose and SCLN but not intervening sites. A ventral view of the head and neck is
shown, with the lower jaw, vomeronasal organ (VNO) which lies ventral to the nasal turbinates, and palate which lies posterior to them, removed. The
palate and VNO are shown separately.
doi:10.1371/journal.ppat.1002346.g001
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Figure 2. Host colonization tracked by Q-PCR. a. DNA was extracted from noses and SCLN at different times after upper respiratory tract infection
(104 p.f.u.), and viral copy number determined byQ-PCR. Viral copy numbers (M2) were normalized according to the cellular copy number (APRT) of the same
sample. Open circles show individual mice (n=6); filled circles showmeans; dashed lines show lower limits of assay sensitivity. Equivalent data were obtained
in 3 replicate experiments. b. The same nose and SCLN samples were analyzed for recoverable virus by plaque assay (noses) and infectious centre assay
(SCLN). Open circles show individual mice; filled circles show means; dashed lines show assay sensitivity limits. Equivalent data were obtained in 2 replicate
experiments. c.During either early lytic replication (day 5) or virus-driven lymphoproliferation (day 14) after nose or lung infections (104 p.f.u.), viral loads were
determined by Q-PCR of the peripheral replication site (nose or lung), draining lymph nodes (SCLN or MLN) and spleen. At day 5, SCLN andmediastinal lymph
node (MLN) viral loads were significantly higher than those in spleens (p,0.001 by Student’s 2-tailed t test). At day 14 they were equivalent. Equivalent data
were obtained in 2 replicate experiments. d.Mice were infected (104 p.f.u.) in either noses or lungs. SCLN and MLN were then pooled from 3 mice per time
point and separated into B cells and DCs on affinity columns. Each population was analyzed for viral DNA by Q-PCR. Viral copy numbers (M2) are expressed
relative to the cellular DNA copy number (APRT). Equivalent data were obtained in 2 replicate experiments. e.Mice were infected as in d. Lymph nodes were
pooled from 3 mice per group at each time point and separated on affinity columns into B cells, DCs and macrophages. Each bar shows mean6 SEM of 3
experiments. For both nose and lung infections, B cell genome loads were significantly high than those of DCs at day 14 and significantly lower at day 5
(p,0.05 by Student’s t test). Viral genome loads were also higher in macrophages than in B cells at day 5 after lung infection (p,0.05), but not at day 5 after
nose infection (p=0.4).
doi:10.1371/journal.ppat.1002346.g002
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Figure 3. Direct visualization of MuHV-4-infected DCs in lymph nodes. a.Mice were infected in the nose (104 p.f.u.) with MuHV-4 expressing
eGFP from an intergenic EF1a promoter. Flow cytometric analysis of SCLN cells 11 days later established that .90% of eGFP+ cells were CD19+,
immunoglobulin+ and MHC class IIhi. .70% were CD69+ and .80% were syndecan-4lo. Equivalent data were obtained in 3 replicate experiments. b.
After an equivalent infection, SCLN sections were co-stained for eGFP and either the B cell marker B220 or the DC marker CD11c. Both eGFP+B220+
MuHV-4 Exploits DCs
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from CD11c-cre transgenic mouse bone marrow by growth in
GM-CSF - albeit less dramatically than in cre+ fibroblasts (Fig. 4c).
Thus eCFP loss provided a minimum estimate of the proportion of
virions passing through a DC.
Functional evidence for MuHV-4 reaching B cells via DCs
We looked for a possible selective effect of eCFP excision by
infecting non-transgenic (cre-) mice with different mixtures of
eCFP+ and eCFP- derivatives of the loxP-eCFP virus, and 20 days
later typing splenic infectious centres for eCFP expression (Fig. 4e).
No marked difference in eCFP+ frequency was observed between
the input and recovered viruses. ECFP loss therefore provided an
unbiased marker of in vivo virus exposure to cre. A limitation of
eCFP-based analysis was that even non-transgenic mice yielded
6.162.8% eCFP- plaques (mean6SD, n= 12). PCR across the
ORF57/58 junction identified loxP recombination in 6/6 eCFP-
plaques recovered from CD11c-cre mice infected with loxP-eCFP
MuHV-4. 3/3 eCFP- plaques recovered from non-transgenic mice
(which were rare) did not show loxP recombination, and were
presumably due to cassette silencing: that viral expression cassettes
are not always active even in lytically infected cells is well-
established [45]. Therefore we took 10% eCFP- plaques (.1 SD
above the background) as indicating significant virus exposure to
cre recombinase.
We then infected CD11c-cre transgenic mice with loxP-eCFP
MuHV-4 in the upper respiratory tract. The infectious virus
recovered from noses showed little eCFP loss above the 10% cut-
off (Fig. 4f). However eCFP loss from SCLN virus was significantly
greater. Therefore DCs contributed relatively little to peripheral
viral lytic replication, and much more to SCLN colonization.
Splenic virus showed no further eCFP loss, consistent with the
spread from the SCLN to here being accomplished by B cells.
Substantial eCFP expression loss from the viruses of flow
cytometrically sorted B cells (Fig. 4f) established that a significant
proportion of the virus establishing long-term latency had passed
through a DC.
The relative inefficiency of cre-mediated eCFP excision in
CD11c-cre mice made it difficult to estimate exactly what
proportion of the virus in B cells had passed through a DC. To
answer this better we exposed DCs grown from CD11c-cre bone
marrow in vitro to MuHV-4 (5 p.f.u./cell, 6 h, 37uC), then washed
them in pH=3 buffer to inactivate non-endocytosed virions and
24 h later - the earliest new infectivity can be recovered from
MuHV-4-exposed DCs - titrated cell supernatants by plaque
assay. ECFP typing under ultra-violet illumination identified
14.263.0% of plaques as eCFP- (mean 6 SD of 10 cultures,
counting at least 100 plaques for each culture). Thus assuming that
an overnight infection of bone marrow-derived DCs equates
roughly in cre exposure to DC-mediated in vivo virus transfer,
essentially all the virus derived from B cells after upper respiratory
tract infection had passed through a DC.
The virus recovered from lungs after lower respiratory tract
infection (Fig. 4g) showed only modest eCFP loss. Unlike after
upper respiratory tract infection, there was no increased eCFP loss
upon reaching the draining lymph nodes (MLN). Therefore lung
infection appeared to provide MuHV-4 with an alternative, DC-
independent route to lymphoid tissue. Viruses recovered from
spleens after lung infection showed more eCFP loss. However,
nose infections inevitably accompany lung infections, so the splenic
virus would also have come from the SCLN. Thus while DCs took
virus to lymph nodes from the upper respiratory tract, they were
less important when a more invasive entry point was used.
Cre-mediated virus inactivation
As a second approach to establishing the functional importance
of DCs for host colonization, we generated a MuHV-4 mutant in
which cre-mediated recombination would cause a lethal genomic
deletion. Thus we inserted between ORFs 8 and 9 a loxP site
compatible with that remaining at the genome left end after BAC
cassette excision (Fig. 5a). Complete recombination between loxP
sites would now excise both the BAC/eGFP cassette and the left
end of the viral genome, including the essential ORFs 6, 7 and 8
[46]. It would also excise the M2 latency gene [47], the viral
tRNA/miRNAs [48] and a likely promoter element for ORF73
[49], and so would probably also compromise the capacity of the
viral genome to persist as a latent episome. Thus in contrast to
eCFP excision from loxP-eCFP MuHV-4, which had no effect on
viral fitness and so provided an index of virus exposure to cre
recombinase, 8/9-loxP MuHV-4 would tell us the functional
consequence of impaired DC infection.
To excise just the BAC cassette from 8/9-loxP MuHV-4 we
passed it once through NIH-3T3-cre cells (2 p.f.u./cell) and
selected viable eGFP- clones. These grew normally in cre- cells, but
were severely attenuated for growth in cre+ fibroblasts (Fig. 5b).
They were moderately attenuated for growth in cre+ DCs. To
confirm the mechanism of attenuation we infected cre- and cre+
fibroblasts with wild-type or 8/9-loxP MuHV-4, then isolated
infected cell DNA, digested it with HinDIII and probed it with a
HinDIII-N viral genomic clone that spans the ORF8/ORF9
junction [50]. Cre-mediated deletion of M1-ORF8 was predicted
to remove the left end of the HinDIII-N locus and join its
remainder to the viral terminal repeats, thereby changing the
probed fragment from 3632 bp to .20 kb (as MuHV-4 has up to
30 copies of its 1.2 kb terminal repeat unit), with a 1.2 kb
submolar ladder due to variation in terminal repeat copy number.
This is precisely what we observed (Fig. 5c).
In vivo consequences of virus inactivation in DCs
8/9-loxP MuHV-4 showed a significant defect in SCLN
colonization at day 7 after inoculation into the noses of CD11c-
cre mice relative to non-transgenic controls, whereas wild-type
MuHV-4 showed no difference (Fig. 6a). An independently
derived 8/9-loxP mutant showed the same phenotype, while a
revertant virus did not (Fig. S2). Therefore DC-specific virus
attenuation reduced virus spread to lymph nodes. A similar cre-
dependent defect was observed in the colonization of B cells,
purified from SCLN by flow cytometric sorting (Fig. 6b). 8/9-loxP
virus lytic titers, by contrast, were not significantly different
between the noses of cre+ and cre- mice (Fig. 6c), consistent with
the limited loss of intergenic eCFP expression seen in noses
(Fig. 4f).
Surprisingly, by day 15 post-infection (spleens and SCLN) the
substantial early defect in SCLN colonization (Fig. 6d) of cre+ mice
by 8/9-loxP MuHV-4 was no longer evident. MuHV-4 single gene
knockouts [51,52] have shown the same phenomenon of early
replication defects not translating into differences in long-term
(arrowheads) and eGFP+CD11c+ cells were readily identifiable. c. SCLN sections analyzed as in b but at 7 days post-infection showed that the eGFP+
cells were almost all CD11c+ and not B220+. The arrowheads show examples. Equivalent data were obtained in 2 replicate experiments. Note that the
sections show representative staining patterns rather than the total level of staining, which was always greater at day 11 than at day 7.
doi:10.1371/journal.ppat.1002346.g003
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latent loads. This possibly reflects that lower virus loads elicit less
host response, such that mutant and wild-type viruses differ more
in their speed of colonization than in their final set points. A
different situation arises when mutant and wild-type viruses
compete for a limited latency niche. To test this we co-infected
cre+ and cre- mice with a 1:100 mix of EF1a-eGFP and 8/9-loxP
viruses (Fig. 6e), and determined their relative levels of host
colonization 30 days later by typing spleen and lymph node
infectious centres as eGFP- or eGFP+. The viruses recovered from
non-transgenic mice showed the expected eGFP+:eGFP- ratio of
1:100. In contrast, those recovered from CD11c-cre mice showed
ratios of 1:3–1:4, a 25-30-fold bias against 8/9-loxP MuHV-4.
Therefore in the face of virus competition, an attenuation of DC
infection substantially reduced host colonization.
MuHV-4 alters the DC cytoskeleton
DCs transport peripherally acquired antigens to lymph nodes
even without viral infection [1]. Therefore MuHV-4 could reach
lymph nodes simply by infecting DCs peripherally and remaining
latent. However, viruses often alter cell behaviour to make host
colonization more efficient. We looked for such effects using DCs
grown from bone marrow stem cells with GM-CSF. After
overnight MuHV-4 infection (3 p.f.u./cell), most bone marrow-
derived DCs are latently infected - typically 20–30% express late
lytic genes [45]. However almost all virus-exposed DCs showed
cytoskeletal changes (Fig. 7a): actin was rapidly relocated to
peripheral cytoplasmic projections, and after overnight infection
the DCs had become flattened with many displaying long
cytoplasmic processes. Phosphotyrosine and more specifically
Y925-phosphorylated (activated) focal adhesion kinase (Fig. 7b)
adopted peripheral, punctate distributions consistent with focal
adhesion formation. MuHV-4-exposed DCs do not become non-
specifically activated [44,53,54], and equivalent cytoskeletal
changes were not induced by DC activation with lipopolysaccha-
ride. Therefore these cytoskeletal changes were induced specifi-
cally by MuHV-4.
Real-time imaging (Video S1) showed that DCs became
flattened and adherent within 6 h of exposure to MuHV-4, yet
continued to show rapid changes in shape. This phenotype
persisted at 20 h post-infection (Video S2), by which time the
combination of adherence and dynamic remodelling and had led
to the long cytoplasmic extensions seen in Fig. 7. Thus it appeared
that infected DCs were motile but unable to detach from plastic.
How these in vitro changes relate to in vivo DC migration is unclear,
as tissue culture plastic provides a rather artificial surface, but it
was clear that MuHV-4 actively manipulates the DC cytoskeleton.
Discussion
Lymphotropic viruses arrive at mucosal epithelia, whereas naive
lymphocytes circulate through organized lymphoid tissue. There-
fore lymphotropic viruses face a problem in reaching their target
cells. Lymphatic channels normally provide a route for DCs and
cell-free antigens to travel from epithelia to lymph node
subcapsular sinuses. Small, soluble antigens can pass directly into
B cell follicles via specialized conduits [55–57], but larger antigens
- immune complexes [58], virus-sized particles [59], and cell-free
virions [60,61] - are first captured by subcapsular sinus
macrophages. Thus viruses can enter lymph nodes via migratory
DCs or subcapsular sinus macrophages.
Most analysis of DC migration has depended on indirect
measures such as T cell priming [62]. In contrast, virion capture
by subcapsular sinus macrophages has been observed directly
[60,61]. However, direct imaging has depended on injecting large
virion numbers. Such high doses may reveal mainly high-capacity
rather than high-efficiency capture pathways, and the tissue
pressures created by injection tend to force material into and along
lymphatics. Therefore the relevance to non-invasive infections of
antigen injections must still be established. Here we analyzed
lymph node colonization after a non-invasive infection. MuHV-4
does not establish a detectable cell-free viraemia [63], and depends
for its in vivo propagation on cell/cell spread [64] more than on
cell-free virion binding [65] or release [66]. Thus it might be
expected to follow a cell-associated route to lymph nodes.
Consistent with this idea, we identified a major role for DCs in
passing infection to B cells. Thus MuHV-4 sets a new precedent
for host exploitation by a lymphotropic virus.
We could not determine whether MuHV-4 reaches lymph
nodes only via DCs, but the similar efficiencies of eCFP excision
and 8/9-loxP virus attenuation between in vitro DC infection and in
vivo host colonization argued that DC infection plays a
predominant role. This would also be consistent with MuHV-4
still infecting the lymph nodes of B cell-deficient mice [67]. CD11c
is a well-established DC marker, but is not exclusive to DCs [68].
Expression on activated T cells can be discounted here as MuHV-
4 does not infect T cells. Lung macrophages express CD11c [68],
as do subcapsular sinus macrophages at a low level [60]. However
lysM-cre mice, which express cre in macrophages [69], showed
substantial eCFP loss from loxP-eCFP MuHV-4 only after lower
respiratory tract infection (unpublished data). Therefore while
macrophages may feature prominently in MuHV-4 lung infection,
DCs provided the major route of its transfer from nose to lymph
nodes. Thus MuHV-4 exploits olfaction to enter the upper
Figure 4. Cre/lox marking of MuHV-4 replicating in DCs. a. The BAC/eGFP cassette at the left end of the MuHV-4 genome is flanked by loxP
sites. An additional eCFP expression cassette with variant loxP sites was inserted between ORFs 57 and 58. After exposure to limited cre recombinase
expression, eCFP+eGFP- viruses could be selected and then assayed for further cre exposure by eCFP loss. b. As outlined in a, NIH-3T3-cre cells were
infected (18 h, 2 p.f.u./cell) with eGFP+eCFP+ MuHV-4, and eCFP+eGFP- viruses selected from the resulting mixed population by flow cytometric sorting
of infected cells and limiting dilution cloning of the virus produced. Further virus exposure to cre by low multiplicity NIH-3T3-cre cell infection led to
eCFP loss. Note that eGFP is driven by an Rta-independent HCMV IE1 promoter and eCFP by an Rta-dependent M3 promoter, so latent or immediate
early lytic infection can be eGFP+eCFP-; with plaque typing this was not an issue because most infection is late lytic. c. ECFP+eGFP- MuHV-4 was tested for
growth and loss of eCFP expression in NIH-3T3 fibroblasts and bonemarrow-derived DCs, each with or without cre expression. Infected cell supernatants
were titered by plaque assay and plaques scored as eCFP+ or eCFP- under ultra-violet illumination. Equivalent data were obtained in 2 replicate
experiments. d. Examples of eCFP+ and eCFP- plaques recovered by infectious centre assay from cre+ mice infected with eCFP+eGFP- MuHV-4. e. Cre-
mice were infected in the nose with different mixtures of eCFP+ and eCFP- MuHV-4 (total 104 p.f.u.). Viruses were recovered 20 days later by infectious
centre of spleen cells and typed for eCFP expression in parallel with a sample of the original inoculum. Equivalent data were obtained in 2 replicate
experiments. f. CD11c-cre+ mice were infected in the upper respiratory tract with eCFP+eGFP- MuHV-4 (104 p.f.u.). Viruses were then recovered from
noses by plaque assay, and from lymph nodes and spleen by infectious centre assay, and scored as eCFP+ or eCFP-. Circles show individual mice; crosses
show means. The proportions of eCFP- plaques were significantly above background (,5% eCFP-) for both noses and lungs (p,0.01 by Student’s t test),
significantly above noses for SCLN (p,0.03) and significantly above noses or lungs for spleens (p,0.01), but not significantly above lungs for MLN
(p= 0.4). Equivalent data were obtained in 2 replicate experiments. g. CD11c-cre+ mice were infected as in f, but in the lower respiratory tract. Viruses
were recovered from lungs by plaque assay, and from lymph nodes and spleen by infectious centre assay.
doi:10.1371/journal.ppat.1002346.g004
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respiratory tract [29]; lymphocytes to persist [70]; and DCs to link
them by virus transport.
Cells migrate by forming cytoplasmic protrusions, adhering
these to the extracellular matrix, then detaching and contracting
their trailing edges [71]. Actin, focal adhesion kinase and tyrosine
phosphorylation all play central roles, so the redistributions of
these markers in infected DCs, independent of viral lytic gene
expression, was consistent with MuHV-4 inducing latently infected
DCs to migrate. ORF27/ORF58-dependent actin rearrangements
[72] could then promote further virion spread upon lytic
reactivation. However, in vitro DC migration was prevented by
infected DCs not detaching from plastic, and we cannot exclude
that the infected SCLN DCs were resident and infected through
antigen capture, rather than being migratory. Therefore virus-
induced DC migration needs further investigation; current
evidence establishes only that DC infection is important for
establishing B cell infection in lymph nodes.
MuHV-4-infected DCs may also promote the amplification of B
cell infection by secreting the M3 chemokine binding protein to
protect in trans against CD8+ T cell attack [73]. In both this setting
and that of virus transfer, the B cell latency defects of MuHV-4
lacking its MHC class I down-regulation gene K3 [51] or its bcl-2
homolog M11 [52] could reflect that these genes function in DCs
[74,75]. Exploiting DCs presumably brings gamma-herpesviruses
advantages of efficiency and stealth. Whether it also creates
possibilities for therapeutic intervention remains to be seen.
Materials and Methods
Mice
All animal experiments were approved by the Cambridge
University ethical review board and by the UK Home Office (PPL
80/1992), and carried out in accordance with the Animals
(Scientific Procedures) Act 1986. C57BL/6 and BALB/c mice
were obtained from Harlan U.K. C57BL/6 back-crossed CD11c-
cre mice, which express cre recombinase in DCs [76], were
obtained from Jackson Laboratories and maintained as heterozy-
gote6C57BL/6 non-transgenic crosses. Mice were typed by PCR
Figure 5. Virus inactivation by cre/lox recombination. a. A loxP site compatible with those flanking the BAC/eGFP cassette was inserted
between MuHV-4 ORFs 8 and 9. After a single passage through NIH-3T3-cre cells (2 p.f.u./cell), we selected viable eGFP- virus clones (8/9-loxP). These
could then be inactivated by further exposure to cre. b.Wild-type (WT) and 89-loxP MuHV-4 were tested for growth after low multiplicity inoculation
of cre+ or cre- NIH-3T3 cells (0.01 p.f.u./cell) and of cre+ or cre- DCs (0.3 p.f.u./cell). Virus titers at each time point were determined by plaque assay of
infected cell supernatants on BHK-21 cells. Equivalent data were obtained in 2 replicate experiments. c. Cre+ and cre- NIH-3T3 cells were infected with
wild-type (WT) or 8/9-loxP MuHV-4 (1 p.f.u./cell, 18 h). Infected cell DNA was digested with HinDIII and hybridized with a probe flanking the 8/9 loxP
site. Cre-mediated recombination was predicted to delete genomic co-ordinates 1–19055), thereby attaching the HinDIII-restricted fragment detected
by a 16237–19868 probe to the terminal repeats. Although residual unrecombined genomes hybridize better with the probe (3631 nt overlap), the
813 nt overlap with recombined genomes was sufficient to identify a terminal repeat ladder.
doi:10.1371/journal.ppat.1002346.g005
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Figure 6. Colonization of CD11c-cre mice by 8/9-loxP MuHV-4. a. CD11c-cre mice (cre+) or non-transgenic littermate controls (cre-) were
infected in the upper respiratory tract with 8/9-loxP or wild-type (WT) MuHV-4 (104 p.f.u.). 7 days later SCLN were analyzed by infectious centre assay
and Q-PCR. Viral genome loads (M2) were normalized by the host genome copy number (APRT) of each sample. Each point shows the result for 1
mouse. The crosses show means. 8/9-loxP MuHV-4 showed a significant defect in cre+ mouse infection (p,0.01 by Student’s t test). Equivalent data
were obtained in 3 replicate experiments. b. CD11c-cre mice (cre+) or non-transgenic littermate controls (cre-) were infected in the upper respiratory
tract with 8/9-loxP MuHV-4 (104 p.f.u.). 7 days later CD19+ B cells were recovered from the SCLN of pooled pairs of mice by flow cytometric sorting
and analyzed by infectious centre assay and Q-PCR. Each point shows the result for 1 mouse. The crosses show means. 8/9-loxP MuHV-4 showed a
significant, cre-dependent defect in both virus recovery from B cells (p,0.01 by Student’s t test) and in B cell viral genome loads (p,0.05). c. Lytic
titers of 8/9-loxP MuHV-4 were determined by plaque assay of noses after upper respiratory tract infection (104 p.f.u.) of CD11c-cre mice or non-
transgenic littermate controls. Each point shows the result for 1 mouse. The crosses show means. No significant difference in titer was observed
between cre+ and cre- mice. Equivalent data were obtained in 2 replicate experiments. d. CD11c-cre mice or non-transgenic controls were infected in
the upper respiratory tract with 8/9-loxP MuHV-4 (104 p.f.u.). SCLN and spleens were then analyzed by infectious centre assay and Q-PCR as in a. The
colonization of cre+ mice was significantly reduced at days 5 and 10 post-infection (p,0.02 by Student’s t test) but not at days 15 or 30. Equivalent
data were obtained in 2 replicate experiments. e. CD11c-cre mice or non-transgenic controls were infected in the upper respiratory tract with a 1:100
mixture of EF1a-eGFP and 8/9-loxP MuHV-4 (total 104 p.f.u.). 30 days later latent virus was recovered from SCLN and spleens by infectious centre
assay and typed as eGFP- or eGFP+. Each point shows the result for 1 mouse. Crosses show means. The proportion of recovered virus that was eGFP+
was significantly increased in cre+ versus cre- mice (p,0.001 by Student’s t test for each organ). Equivalent data were obtained in 2 replicate
experiments.
doi:10.1371/journal.ppat.1002346.g006
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of tail DNA, using the primers 59-ACTTGGCAGCTGTCTC-
CAAG, 59-GCGAACATCTTCAGGTTCTG (transgene-specific)
and 59 CAAATGTTGCTTGTCTGGTG, 59- GTCAGTC-
GAGTGCACAGTTT (internal control). Mice were infected with
MuHV-4 when 6–12 weeks old. Intranasal infections with
anaesthesia were in 30 ml; those without were in 5 ml. For
luciferase imaging, mice were injected intraperitoneally with
luciferin (2 mg/mouse), anaesthetized with isoflurane, then
scanned with an IVIS Lumina (Caliper Life Sciences). To image
specific tissues mice were killed and dissected after luciferin
injection. All experiments conformed to local animal ethics
regulations and Home Office Project Licence 80/1992.
Cells
Baby hamster kidney (BHK-21) cells, NIH-3T3 cells and NIH-
3T3-CRE cells [50] were propagated in Dulbecco’s modified
Eagle medium (Invitrogen Corporation) supplemented with 2 mM
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and
10% fetal calf serum (complete medium). Dendritic cells were
derived from bone marrow progenitors of CD11c-cre mice or non-
transgenic litter-mates. Bone marrow cells were depleted of
adherent cells (30 min, 37uC) and then cultured in RPMI with
10% fetal calf serum, 50 mM 2-mercaptoethanol, 100 U/ml
penicillin, 100 mg/ml streptomycin and 7.5 ng/ml GM-CSF
(PeproTech). The medium was changed every 2 d, and non-
adherent cells harvested after 7 d. These were .90% GR-
1-CD11c+ by flow cytometry.
Bead-based cell separation
Lymph nodes were removed post-mortem, finely minced,
digested (20 min) with type II collagenase (1 mg/ml, Worthington
Biochemicals) plus DNaseI (20 mg/ml, Boehringer Mannheim),
then incubated (5 min) in 100 mM EDTA to disrupt cell/cell
conjugates. Debris was removed by filtration (100 mm). B cells,
DCs and macrophages were then separated with antibody-coated
magnetic beads (Miltenyi Biotec). First B cells were selected with
anti-CD45R, then DCs were selected with anti-CD11c, then
macrophages were selected with anti-CD11b. Each population
was .90% pure by flow cytometry.
Viruses
Luciferase+ [29], EF1a-eGFP+ (May and Stevenson, 2010), and
gM-eGFP+ [77] MuHV-4 reporter viruses have been described.
To insert a floxed eCFP expression cassette into the MuHV-4
genome, the eCFP coding sequence was amplified by PCR (Pfu
ploymerase, Promega Corporation) from pMSCV-IRES-eCFP
using EcoRI and KpnI-restricted primers which also incorporated
modified loxP sites. Specifically the GCATACAT spacer region
was changed to GTATACAT [78] = loxP*. The loxP*-flanked
eCFP coding sequence was then cloned as an EcoRI/KpnI-
restricted fragment into the corresponding sites of pSP73-M3-pA
[79]. This placed it between a 500 bp MuHV-4 M3 promoter and
a bovine growth hormone polyadenylation site. The M3-driven
eCFP expression cassette was then excised from pSP73-M3-pA
with BglII+XhoI, blunted with Klenow fragment DNA polymerase
and cloned into the blunted MfeI site (genomic co-ordinate 77176)
[80] of a BglII MuHV-4 genomic clone (co-ordinates 75338–
78717), again in pSP73. This placed it between the 39 ends of
ORFs 57 and 58. The eCFP expression cassette plus genomic
flanks was then subcloned as a BglII fragment into the BamHI site
of the pST76K-SR shuttle vector and recombined into a MuHV-4
BAC [44].
To insert a loxP site into the MuHV-4 genome between ORF8
(genomic coordinates 16526–19054) and ORF9 (genomic coordi-
nates 19217–22300), we amplified by PCR 2 genomic flanks
around genomic coordinate 19055, generating the loxP site from
overlapping 39 extensions of the inner primers. The 2 PCR
products were then mixed and re-amplified with the outer primers
to generate a single product. A SmaI/BglII-restricted fragment,
corresponding to genomic coordinates 18614–19424 with the new
loxP site at 19055, was then excised from this product, cloned into
the SmaI/BamHI sites of pST76K-SR, and recombined into the
MuHV-4 BAC. Mutant viruses were identified by restriction
enzyme mapping and by DNA sequencing across the insertion site.
We also derived a revertant virus by shuttle vector-mediated
reconstitution of the original genome region without a loxP site.
BAC DNA was reconstituted into infectious virus by transfection
into BHK-21 cells (Fugene-6, Roche Diagnostics). The floxed
BAC/GFP cassette was removed by virus passage through NIH
3T3-CRE cells, followed by plaque purification. Virus stocks were
prepared in BHK-21 cells. Infected cell debris was removed by
centrifugation (4006g, 3 min), and virions then recovered from
supernatants by ultracentrifugation (380006g, 90 min).
Infectivity assays
Virus stocks were titered by plaque assay on BHK-21 cells [66].
Cell monolayers were incubated with virus dilutions (2 h, 37uC),
overlaid with 0.3% carboxymethylcellulose, and 4 days later fixed
in 4% formaldehyde and stained with 0.1% toluidine blue for
plaque counting. Infectious virus in lungs and noses was measured
by freeze-thawing the tissues, then homogenizing them in 1 ml
complete medium prior to plaque assay. Latent virus was
measured by infectious centre assay [66]: spleen cells were co-
cultured with BHK-21 cells, then fixed and stained for plaque
counting after 4 days. Plaque assay titers of freeze-thawed
lymphoid homogenates were always ,1% of infectious center
assay titers, so the latter essentially measured reactivable latent
virus. To distinguish eCFP+ and eCFP- (or eGFP+ and eGFP-)
viruses, plaque or infectious centre assays were performed in
limiting dilution format. Each well was then scanned under
normal illumination, and for each positive well a chosen plaque
scored as fluorescent or not under ultra-violet illumination. Thus
each positive well was counted just once.
Viral genome quantitation
MuHV-4 genomic co-ordinates 4166–4252, corresponding to
the M2 locus, was amplified from tissue DNA (50–80 ng) by
quantitative PCR (Rotor Gene 3000, Corbett Research). The
PCR products were quantitated by hybridization with a Taqman
probe (genomic coordinates 4218–4189) and converted to genome
Figure 7. Modification of the DC cytoskeleton by MuHV-4. a. Bone marrow-derived DCs were left uninfected or exposed to gM-eGFP+ MuHV-
4 (2 p.f.u./cell) for the time shown. The cells were then fixed, permeabilized and stained for actin with Alexa568-coupled phalloidin (red). EGFP
fluorescence was visualized directly (green) and nuclei were counterstained with DAPI (blue). gM is a late lytic gene, so any eGFP signal seen before
20 h is likely to be from input virions. Equivalent data were obtained in 2 replicate experiments. b. Bone marrow-derived DCs were left untreated,
exposed to 1 mg/ml LPS for 6 h, or exposed to EF1a-eGFP+ MuHV-4 (3 p.f.u./cell) for 6 h or 20 h. The cells were then fixed, permeabilized and stained
for actin, phosphotyrosine (pTyr) or phosphorylated focal adhesion kinase (pFAK) (red). Nuclei were counter-stained with DAPI (blue) and eGFP
fluorescence was visualized directly (white). Equivalent data were obtained in 2 replicate experiments.
doi:10.1371/journal.ppat.1002346.g007
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copies by comparison with a standard curve of cloned plasmid
template amplified in parallel [81]. Cellular DNA was quantitated
in parallel by amplifying part of the adenosine phosphoribosyl
transferase gene.
Southern blotting
Viral DNA was extracted by alkaline lysis [66], digested with
HinDIII, electrophoresed and transferred to nylon membranes
(Roche Diagnostics). A 32P-dCTP labelled probe (APBiotech) was
generated by random primer extension (DECA prime II kit,
Ambion). Membranes were hybridised with probe (65uC, 18 h),
washed in 30 mM sodium chloride/3 mM sodium citrate/0.1%
sodium dodecyl sulfate at 65uC and exposed to X-ray film.
Flow cytometry
Cells infected with eCFP+ or GFP+ viruses were trypsinized,
washed in PBS and analysed directly for eGFP and eCFP
fluorescence on a Fortessa flow cytometer (BD Biosciences). For
specific staining of lymph node cells, IgG Fc receptors were blocked
by pre-incubation (30 min, 4uC) with unlabelled rat anti-CD16/
32 mAb, then stained for CD19, CD69, MHC class II or syndecan-
4 with phycoerythrin-conjugated rat mAbs (all from BD Bioscienc-
es) and for surface immunoglobulin with Alexafluor 633-conjugated
goat anti-mouse Ig(H+L) pAb (Invitrogen). After washing, cells were
analysed on a FACS Calibur using Cellquest (BD Biosciences) and
Weasel (Walter and Eliza Hall Institute of Medical Research). For
flow cytometric sorting, spleen cells were pooled from pairs of mice
and stained with phycoerythrin-conjugated rat anti-mouse
CD19 mAb and Alexafluor 633-conjugated goat anti-mouse
Ig(H+L) pAb. CD19+Ig+ cells were selected with a FACS Vantage
(BD Biosciences). The recovered cells were .98% pure.
Immunofluorescence
DCs were plated overnight onto poly-D-lysine-coated coverslips
after 7 days of culture, then infected or not with MuHV-4. After
further culture, the cells were washed with PBS, fixed in 2%
formaldehyde, permeabilized with 0.1% Triton-X-100, blocked
with 3% BSA and stained for actin with Alexafluor568-conjugated
phalloidin (Invitrogen), for phospho-tyrosine with mAb PY99
(Santa Cruz Biotechnology) plus Alexafluor568-conjugated goat
anti-mouse pAb (Invitrogen), and for Y925-phosphorylated focal
adhesion kinase with ab38512 (AbCam) plus Alexafluor568-
conjugated goat anti-rabbit pAb (Invitrogen). EGFP fluorescence
was visualized directly. After washing in PBS, the cells were
mounted in Prolong Gold with DAPI (Invitrogen) and imaged
with a Leica Confocal microscope.
Lymph nodes were removed post-mortem, fixed (24 h, 4uC) in
1% formaldehyde/10 mM sodium periodate/75 mM L-lysine,
then equilibrated in 30% sucrose, and frozen in OCT mounting
medium. 5 mm sections were blocked with 2% goat serum then
stained for CD45R (mAb RA3-6B2, B cells) or for CD11c (mAb
HL3, DCs) (BD Biosciences) plus Alexafluor568 or 488-conjugated
goat anti-rat or anti-hamster IgG pAb (Invitrogen). Infected cells
were detected with rabbit anti-eGFP pAb (Abcam) plus Alexa-
fluor488 or 568-conjugated goat anti-rabbit IgG pAb (Invitrogen).
The sections were mounted in Prolong Gold (Invitrogen) and
imaged with a Leica Confocal microscope.
Supporting Information
Figure S1 Replication of loxP-eCFP MuHV-4 in cre-
mice. a. C57BL/6 mice were infected in the upper respiratory tract
with wild-type or loxP-eCFP MuHV-4 (104 p.f.u.). 6 days later noses
were titered for infectious virus by plaque assay. Each point shows the
result for 1 mouse. The crosses show means. b. C57BL/6 mice were
infected as in a. 16 days later spleens were titered for recoverable
latent virus by infectious centre assay. Each point shows the result for
1 mouse. The crosses show means. LoxP-eGFP MuHV-3 showed no
significant defect in either lytic or latent infection.
(TIF)
Figure S2 SCLN infection of cre+ mice. CD11c-cre mice
were infected in the upper respiratory tract with wild-type (WT)
MuHV-4, the 8/9-loxP mutant, an independently derived mutant
(ind) or a revertant virus (rev) (all 104 p.f.u.). 7 days later SCLNwere
analyzed for virus colonization by infectious centre assay. Each
point shows the result for 1 mouse. The crosses showmeans. The 8/
9-loxP mutants both showed a significant infection defect (p,0.002
by Student’s t test), whereas the revertant virus did not (p= 0.48).
(TIF)
Video S1 Bone marrow-derived DCs were infected with
gM-eGFP+ MuHV-4 (3 p.f.u./cell) and imaged 6 h later
by time-lapse confocal microscopy (Leica). Images were
recorded every 8 sec over 7 min. The left-hand panel shows eGFP
fluoresence and the right-hand panel the corresponding phase contrast
image. At 6 h after exposure to MuHV-4, DCs show little late lytic
gene expression. Thus the eGFP signal comes from the input virions.
The non-adherent DCs correspond to those more activated prior to
virus exposure, which are poorly infected and so remain eGFP-. The
DCs taking up virions, and presumably becoming infected, show
flattening, adherence to plastic and marked cytoplasmic motility.
(AVI)
Video S2 Bone marrow-derived DCs were infected as in
Video S1 and imaged 20 h later. Images were recorded every
8 sec over 7 min. The left-hand panel shows eGFP fluoresence and
the right-hand panel the corresponding phase contrast image. The
infected DCs (eGFP+) remain dynamic, consistent with actin
remodelling, but are firmly adherent to plastic. This has led to the
formation of long cytoplasmic processes.
(AVI)
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